AAAAAA

   
Results: 1-8 |
Results: 8
AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR PATIENTS WITH ADVANCED HODGKINS-DISEASE (HD)
Authors: KAKKAS I KARMIRIS T MALEKOU S BALTATHAKIS I GIGANTES S GIANNAKAKIS A PAGONIS M KARAKASIS D SKANDALIS A HARHALAKIS N NIKIFORAKIS E
Citation: I. Kakkas et al., AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR PATIENTS WITH ADVANCED HODGKINS-DISEASE (HD), Bone marrow transplantation, 21, 1998, pp. 571-571
AUTOLOGOUS TRANSPLANTATION WITH ACTIVATED MARROW
Authors: KARAKASSIS D MALEKOU S GIANNAKAKI A SKANDALIS A HARHALAKIS N KAPSIMALIS V KARATZA M TZIOTZIOU I PAGONIS M KARMIRIS T NIKIFORAKIS N
Citation: D. Karakassis et al., AUTOLOGOUS TRANSPLANTATION WITH ACTIVATED MARROW, Bone marrow transplantation, 21, 1998, pp. 572-572
SPECTRUM OF HEMATOLOGICAL DISORDERS IN COMMON VARIABLE IMMUNODEFICIENCY (CVI) AND IGA DEFICIENCY (IGA-D)
Authors: CHRYSOVERGI D TSIROYIANNI A PAPPAS H KAPSIMALI V BAKIRI M KARMIRIS T DERVENOULAS J MERZANOS E KONSTANTINIDIS J HALEVELAKIS G ECONOMIDOU J
Citation: D. Chrysovergi et al., SPECTRUM OF HEMATOLOGICAL DISORDERS IN COMMON VARIABLE IMMUNODEFICIENCY (CVI) AND IGA DEFICIENCY (IGA-D), Molecular immunology, 35(11-12), 1998, pp. 748-748
SHORT-DURATION PREEMPTIVE THERAPY WITH GANCICLOVIR FOR THE MANAGEMENTOF CYTOMEGALOVIRUS-INFECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANT
Authors: BALTATHAKIS I GOUGOPOULOU D KOLOVOU A KAKKAS I AXARLIS S KARMIRIS T KARAKASIS D SKANDALIS A HARHALAKIS N NIKOFORAKIS E
Citation: I. Baltathakis et al., SHORT-DURATION PREEMPTIVE THERAPY WITH GANCICLOVIR FOR THE MANAGEMENTOF CYTOMEGALOVIRUS-INFECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANT, Blood, 88(10), 1996, pp. 3770-3770
IS THERE ANY BENEFICIAL EFFECT OF IGIV IN THE EARLY POSTOPERATIVE COURSE OF SPLENECTOMIZED PATIENTS
Authors: MAVROMATIS T KARMIRIS T MITSOULI C DASKALAKIS K IUBAS L
Citation: T. Mavromatis et al., IS THERE ANY BENEFICIAL EFFECT OF IGIV IN THE EARLY POSTOPERATIVE COURSE OF SPLENECTOMIZED PATIENTS, British Journal of Surgery, 82, 1995, pp. 73-73
BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (VP-16) AS A PREPARATIVE REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: SKANDALIS A MALEKOU S POULAKIDAS E TSIONOS K KAKKAS J KATOPI D KARMIRIS T KARAKASIS D HARHALAKIS N NIKIFORAKIS E
Citation: A. Skandalis et al., BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (VP-16) AS A PREPARATIVE REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 86(10), 1995, pp. 3855-3855
THE MANAGEMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA AT A SINGLE-CENTER OVER A 24-YEAR PERIOD - PROGNOSTIC FACTORS FOR SURVIVAL
Authors: KARMIRIS T ROHATINER AZS LOVE S CARTER M GANJOO RK AMESS J NORTON AJ LISTER TA
Citation: T. Karmiris et al., THE MANAGEMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA AT A SINGLE-CENTER OVER A 24-YEAR PERIOD - PROGNOSTIC FACTORS FOR SURVIVAL, Hematological oncology, 12(1), 1994, pp. 29-39
TRANSPLANT-RELATED MORTALITY (TRM) - THE EXPERIENCE OF A NEW BONE-MARROW TRANSPLANT UNIT
Authors: APOSTOLIDIS J HARHALAKIS N SKANDALIS A KATOPI D SAKELLARIOU K KARAKASIS D KARMIRIS T NIKIFORAKIS E
Citation: J. Apostolidis et al., TRANSPLANT-RELATED MORTALITY (TRM) - THE EXPERIENCE OF A NEW BONE-MARROW TRANSPLANT UNIT, Blood, 84(10), 1994, pp. 10000703-10000703
Risultati: 1-8 |